Talat Soner Yilmaz

Talat Soner Yilmaz

Auto-generated profile, based on publicly available information

Talat Soner Yilmaz

Internal Medicine, Şanlıurfa Mehmet Akif İnan Training and Research Hospital, Sanlıurfa, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in New Emirates Medical Journal
Verified
Journal Article
Open access
PDF file
AAAli AKIN
Ali AKIN
TYTalat Soner Yilmaz
Talat Soner Yilmaz
Background: Crush syndrome is the second most common cause of death in earthquakes, following direct trauma. Crush syndrome develops when toxic substances released after tissue injury or crushing reach the bloodstream. The aim of this study was to investigate factors associated with morbidity and mortality in patients rescued from the rubble after the February 6 earthquake and admitted to our hospital who had crush syndrome by retrospectively analyzing their data. Methods: Hemodialysis, fasciotomy, and other parameters during hospitalization and time to transfer to a ward or death of 36 adult patients with crush syndrome who were rescued from the rubble and hospitalized after the February 6 earthquake were retrospectively analyzed. Results: Thirty-six patients were included in the study. There was no significant correlation between the mortality of patients according to their time of rescue or need for fasciotomy, dialysis, or inotropes (p=0.767, p=0.294, p=0.625, p=0.865, respectively). There was a high inverse correlation between the time of rescue and time to death. There was a weak inverse correlation between the time of rescue and hospitalization duration (r=-0.767 and r=-0.341, respectively). There was a significant correlation between the need for inotropes and mortality (p<0.001). No one who didn't need dialysis passed away. Dialysis was necessary for all six of the deceased individuals. We can conclude that one significant factor in predicting death in CS patients is the requirement for dialysis. Conclusion: Crush syndrome, which develops in patients rescued from the rubble alive, is a life-threatening condition. It is an important syndrome and an important cause of mortality for earthquake victims. Further large-scale studies are needed to elucidate the association of time of rescue, the need for fasciotomy and hemodialysis, and other factors with mortality.

20 January 2023 in Sağlık Bilimlerinde Değer
Verified
Journal Article
Open access
PDF file
AAAli AKIN
Ali AKIN
YSYılmaz Safi̇
Yılmaz Safi̇
TYTalat Soner Yilmaz
Talat Soner Yilmaz
Amaç: Koronavirüs-19 hastalığına (COVID-19) bağlı gelişen sitokin fırtınasının (SF) mortalite ve morbiditeyi etkilemede önemli olduğu düşünülmektedir. Çalışmamızda yoğun bakım kliniğinde SF nedenli yatan hastalarda tosilizumab ile anakinranın etkinliklerinin karşılaştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya Ocak 2021-Aralık 2021 tarihleri arasında SF gelişen 69 hasta alındı. Anakinra veya tosilizumab tedavisi alan hastaların aldıkları tedavi süreleri ve dozları, daha önce aldıkları tedaviler (favipiravir ve pulse steroid) kayıt altına alındı. Hastaların biyokimyasal parametreleri retrospektif olarak incelendi. Bulgular: Sitokin fırtınası olan olguların 42’si (% 60,9) anakinra, 27’si (% 39,1) tosilizumab kullanmıştı. Olguların % 39,1’i (n=27) kadın, % 60,9’u (n=42) erkekti. Olguların yaşları 27 ile 89 arasında değişmekte olup, ortalama yaş 56,27±13,87 yıl olarak saptandı. İki grup arasında tedavi öncesi ve 48. saatte bakılan; beyaz küre (Wbc), lenfosit, nötrofil, ferritin, C Reaktif Protein (CRP), prokalsitonin, fibrinojen, D-dimer, kreatinin değerleri benzerdi (p> 0,05). Anakinra tedavisi alan 42 hastanın 21’i (% 50) exitus oldu, 21’i (% 50) servise alındı. Tosilizumab tedavisi alan 27 hastanın 23’ü (% 85,2) exitus oldu, 4’ü (% 14,8) servise alındı. Anakinra ve tosilizumab arasında mortalite açısından anlamlı fark olduğu tespit edildi (p= 0,014). Sonuç: Çalışmamızda COVID-19 nedenli SF gelişen hastalarda anakinra tedavisi, tosilizumaba göre mortalite açısından üstün bulunmuştur.